In women, these long-term complications most likely arise from pelvic inflammatory disease (PID), which is the result of the damage caused by bacteria reaching the uterus and oviducts. Pelvic inflammatory disease (PID) could then be used as an endpoint. However, PID clinical diagnosis is not selleck chemicals precise enough and calls for a more specific case definition. In addition, PID can be caused by any of these three pathogens, chlamydia [1] and [30],

gonorrhea [1] and [31] and trichomonas [32] and [39], and may also be related to other conditions such as bacterial vaginosis [40]. Therefore, tests to identify the cause of PID, as well as tests capable of differentiating infection from vaccination will have to be performed. The fact that chlamydia, gonorrhea and trichomonas all lead to PID and reproductive tract complications pleads for the development

of a vaccine against each of these diseases, preferably a trivalent vaccine, protecting against the three pathogens. They will, however, have to be tested separately. The greatest public health impact of STIs is perhaps their role in enhancing transmission of HIV-1 infection, in males as well as in females. Prevention of these STIs would have a Dolutegravir major impact on the HIV epidemic. However, it is doubtful that this can be demonstrated Adenosine in a clinical trial. Even partially protective vaccines or disease modifying vaccines could potentially provide important benefits by reducing transmission. Modeling studies have shown that even moderate reductions in peak load and duration of infection could have major effects on chlamydia epidemiology [38] and [41]. However, disease-modifying vaccines could also possibly increase transmission, if

vaccination results in increased asymptomatic infections, and/or reduced testing and screening, or increased risky behaviors, an issue that was raised in modeling studies of HIV vaccines [42]. If a vaccine reduced symptoms of gonorrhea in men, it would make the infection much harder to control, because one key feature that makes gonorrhea easy to control is the high proportion of men with early and significant symptoms. Another important barrier to the development of STI vaccines is the low perception of the disease burden, the lack of a clear demand for a vaccine, and the uncertainties of the market. This is particularly true for gonorrhea and trichomonas. As long as the burden is considered as negligible, there is little motivation for public research, funding agencies and industry. And yet, the available epidemiological data clearly show that STIs are a global public health concern. An estimated 536 million people aged 15–49 years have a chronic HSV-2 infection.